Category: Uncategorised

Celebrating Success: Two CNTN endorsed trials selected for funding by CIHR’s ACT Consortium

Posted on

Congratulations to Drs. Sam Silver, Amber Molnar and Ann Young and teams for being selected for funding by the Accelerating Clinical Trials (ACT) Consortium! Stream 1 for this request for applications was dedicated to novel trial designs. With a total funding pool of $1.5 million, 2 of the 8 trials selected were CNTN endorsed trials:

 

Dr. Samuel Silver (Kingston, ON; Queens University) and Dr. Amber Molnar (Hamilton, ON; McMaster University): Dial-Bicarb: The Dial-Bicarb Trial investigates dialysate bicarbonate levels
 

Dr. Ann Young (Toronto, ON; Unity Health Toronto and St. Michael’s Hospital): KidneyCare Outreach: Vanguard phase of a population-based randomized clinical trial to strengthen kidney care delivery for patients at high risk of kidney failure

 

You can see the full list of awarded trials here

The ACT Consortium was established to advance and facilitate the implementation of high-quality, high-impact randomized controlled trials (RCTs) to improve global health. For more information on the consortium, visit www.act-aec.com.

Celebrating Success: Two CNTN endorsed trials selected for funding by CIHR’s ACT Consortium

Posted on

Congratulations to Dr. Michael Walsh and Dr. Amit Garg and teams for being selected for funding by the Canadian Institutes for Health Research (CIHR)’s Accelerating Clinical Trials (ACT) Consortium! Of the 43 trials that applied for funding, 2 of the 11 trials selected were CNTN endorsed trials: 

 

Dr. Amit Garg (London, ON; Western University and the London Health Sciences Centre): Effect of a Multi-Component Quality Improvement Intervention on Patient Access to Kidney Transplantation and Living Kidney Donation (EnAKT-LKD)
 

Dr. Michael Walsh (Hamilton, ON; McMaster University and the Population Health Research Institute): Aldosterone blockade for Health Improvement Evaluation in End-stage renal disease (ACHIEVE) 

 

The ACT Consortium was established to advance and facilitate the implementation of high-quality, high-impact randomized controlled trials (RCTs) to improve global health. For more information on the consortium, visit www.act-aec.com.
 

This most recent call for proposals was designed to support ongoing and active, Canadian-led, high-impact RCTs that required additional funding for successful completion. All recipients of this ACT grant will publicly report their results by January 15, 2025. 

 

We look forward to learning their results! 

First virtual symposium

Posted on

 

Thank you to all of those who attended our first virtual symposium. It was a great success and we are excited to host another in early 2021. If you are interested in presenting, please email Alicia at amurdoch@cansolveckd.ca.

For those who were unable to attend, you can view the recording of the session here. Listed below are the start times of the individual presentations and their titles:

Dr. Sam Silver presents his trial, Promoting Kidney Recovery after Acute Kidney Injury Receiving Dialysis, at 11:20.

Dr. Bhanu Prasad presents his trial, Renal denervation in patients with loin pain hematuria syndrome – a feasibility study, at 43:05.

Dr. Ron Wald gives an update on the PHOSPHATE trial, Pragmatic randomized trials of High Or Standard PHosphAte Targets in End-stage kidney disease, at 1:20:50.

Dr. Michael Walsh discuss the recruitment challenges with his multi-centre, multi-country trial – ACHIEVE, Aldosterone Blockade for Health Improvement Evaluation in End Stage Renal Disease, at 1:58:40.

 

OPTIONS Vasculitis study looking for patients

Posted on

If you’re a patient with vasculitis or kidney disease that lives in Canada, the United Kingdom, or the United States, please help us out by taking 15 minutes to complete a survey regarding patient value and preferences about plasma exchange in ANCA associated vasculitis.

https://www.surveymonkey.com/r/optionsvasculitis

All responses are anonymous. Your answers will help patients and doctors with shared decision making about plasma exchange in patients with vasculitis and kidney disease as well as inform clinical practice guidelines. Thanks!

Cannabis survey looking for participants

Posted on

Dr. David Collister, CNTN Scientific Operations and Executive committee member, is co-principal investigator on a study, “CANNAbis for the treatment of symptoms in advanced CKD and dialysis: a patient survey (CANNA-CKD)”

This study is an online survey of adults with kidney disease (including chronic kidney disease, dialysis or transplant). The survey consists of 15 questions and should take no longer than 10 minutes to complete. It collects information about your use of recreation and medicinal cannabis use.

The goal of this survey is to determine the recreational and medicinal cannabis experiences of patients with advanced chronic kidney disease or those on dialysis. We would also like to evaluate your willingness to participate in future studies of cannabis for symptoms related to kidney disease.

All responses are anonymous and it does not collect any personal health information. The results of this survey (and a physician survey) will be used to determine which symptoms to pursue funding for clinical trials of cannabis in patients with kidney disease. The results of the physician survey were recently published and can be found here.

The survey is available at https://www.surveymonkey.com/r/TCCWJFX. For questions related to the survey, please contact Dr. Collister at david.collister@phri.ca.